Non-coding RNAs (ncRNAs), once considered the 'dark matter' of the genome, have now emerged as pivotal regulators in cancer ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, presented data today from a study showing that its ...

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

Researchers from the University of Eastern Finland, Aalto University and the University of Oulu have developed a new ...

The pre-analytical workflow is one of the primary considerations in the successful use of liquid biopsies for cancer ...

Galleri blood test detects fifty cancers early via cfDNA analysis for adults 50+ with no symptoms, though not a standard ...

Fellow Health, a company focused on advancing male reproductive health through patient-centric testing solutions, today announced the presentation of four posters at the American Urological ...

Cold' tumors are resistant to common immunotherapies. Researchers have uncovered a master regulator that can be manipulated to prevent tumor growth in mice.

Researchers from the Endocrine Tumors group at the Germans Trias i Pujol Research Institute (IGTP), in collaboration with ...

Guardant Health partners with Pfizer to support oncology drug development using smart liquid biopsy tech and expand testing access in China.

Tumor-infiltrating clonal hematopoiesis (TI-CH) increased the risk of disease recurrence or death among patients with early ...